Cedar Mountain Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cedar Mountain Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.9K	Hold	363	–	–	﹤0.01%	325
2026 Q1	$22K	Buy	363 +302	+495%	+$17.6K	﹤0.01%	277
2025 Q4	$3.29K	Sell	61 -24	-28%	-$1.16K	﹤0.01%	352
2025 Q3	$3.83K	Buy	+85	New	+$3.97K	﹤0.01%	356
2023 Q3	–	Sell	-158	Closed	-$10.1K	–	315
2023 Q2	$10.1K	Hold	158	–	–	﹤0.01%	167
2023 Q1	$11K	Hold	158	–	–	﹤0.01%	158
2022 Q4	$11.4K	Hold	158	–	–	﹤0.01%	152
2022 Q3	$11K	Hold	158	–	–	﹤0.01%	151
2022 Q2	$12K	Hold	158	–	–	﹤0.01%	147
2022 Q1	$12K	Hold	158	–	–	﹤0.01%	155
2021 Q4	$10K	Hold	158	–	–	﹤0.01%	173
2021 Q3	$9K	Hold	158	–	–	﹤0.01%	175
2021 Q2	$11K	Sell	158 -1	-0.6%	-$65	﹤0.01%	159
2021 Q1	$10K	Hold	159	–	–	﹤0.01%	167
2020 Q4	$10K	Hold	159	–	–	﹤0.01%	172
2020 Q3	$10K	Hold	159	–	–	﹤0.01%	156
2020 Q2	$9K	Buy	+159	New	+$9.51K	﹤0.01%	157

Other funds holding BMY

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Cedar Mountain Advisors's BMY Position: Q2 2026 in Review

Cedar Mountain Advisors held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 363 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #325.

Cedar Mountain Advisors first reported a position in BMY in Q2 2020 and has held it in 17 quarters since. The position peaked at $22K in Q1 2026. 796 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Cedar Mountain Advisors held 363 shares of Bristol-Myers Squibb worth $20.9K as of Q2 2026.
Cedar Mountain Advisors left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #325 holding.
Cedar Mountain Advisors first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 17 quarters since.
Cedar Mountain Advisors's Bristol-Myers Squibb position peaked at $22K in Q1 2026.
796 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.